Structure-Activity Relationship (SAR); L-type amino acid transporter 1 (LAT1).
Introduction
A member of the Solute Carrier Transporter Family (SLC), System L includes L-Amino Acid Transporter 1 (LAT1), LAT2, LAT3, and LAT4. 1-4 LAT1 and LAT2 belong to SLC7, while LAT3 and LAT4 belong to SLC43. It is well established that LAT1 and LAT2 require the heavy chained 4F2hc chaperone protein for amino acid transport activity, whereas LAT3 and LAT4 do not. 5 LAT1 and LAT2 are hetero-dimeric large amino acid transporters expressed in various tissues and appear to act as 1:1 exchangers in concert with other amino acid transporters. LAT1 and LAT3 appear to be selectively expressed in tumor cells 3, 6 ; consequently we regard these transporter proteins as potential oncology drug targets. In contrast to LAT1, LAT2's mRNA has low expression in tumor cells, but expressed with high frequency in normal tissues. 2 Furthermore, it has been shown that many primary human tumors and tumor cell lines (e.g. uterine cervical carcinoma cells (i.e. HeLa), bladder carcinoma cells (i.e. T24), and lung small-cell carcinoma cells (i.e. RERF-LC-MA) highly express LAT1. 6 In a rat liver metastases model, LAT1 expression correlated well with tumor cell growth. 7 LAT1 over-expression has also been reported in pulmonary adenocarcinoma and esophageal carcinoma. 8, 9 LAT1 expression was investigated in sixty patients with astrocytic brain tumors and statistical analysis illustrated that high LAT1 expression correlated with limited survival. 10 Furthermore, it was recently reported that LAT1 expression is a pathological factor that predicts the prognosis of non-small cell lung cancer (NSCLC) and prostate cancer. 11, 12 Hence, the experimental data demonstrate that cancerous and/or proliferating cells in vivo are strongly linked to LAT1 expression.
In 1998, LAT1 expression cloning was first reported and we initially probed LAT1's structureactivity relationship (SAR) by conducting experiments using rat LAT1 (rLAT1) and 4F2hc expressed in the Xenopus laevis oocyte system. 1 These data provided initial insight regarding LAT1 substrate recognition. 13 In those experiments, both uptake and efflux experiments were conducted using [ 14 C]phenyl-alanine 1 as a model substrate. Consistent with competitive inhibition, LAT1mediated uptake was strongly inhibited by aromatic-amino acid derivatives such as L-dopa 2, methyldopa 3, melphalan 4, triiodothyronine 5, and thyroxine 6. In contrast, phenylalanine methyl ester 7, N-methyl phenylalanine 8, dopamine 9, tyramine 10, carbidopa 11, and droxidopa 12 did not inhibit [ 14 C]phenyl-alanine uptake (Table 1, oocyte data). These in vitro data supported the notion that small aromatic amino acids require the free carboxylic acid (i.e. non-ester) and amino group (i.e. no alkyl groups on the amine) in order to be an LAT1 substrate. 13 While the oocyte expression system was a useful and informative in vitro system, we sought to develop methods amendable for compound high throughput screening (HTS) and a system to study human (i.e. hLAT1 and hLAT2). In 2008 we reported the establishment of a mammalian cell line expressing hLAT1 or hLAT2 14 ; we refer to these two cell lines as S2-hLAT1 and S2-hLAT2, respectively. These cell lines afford robust in vitro cell based tools to evaluate the interaction of known and novel compounds to chemically compare hLAT1 versus hLAT2. In this model, we use [ 14 C]L-leucine uptake to investigate the structural and inhibitory differences between hLAT1 and hLAT2. S2-hLAT1 cells are inhibited by L-isomers of leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan, methionine, Copyright 2019 KEI Journals. All Rights Reserved http://journals.ke-i.org/index.php/mra histidine, and a classical SL specific inhibitor, 2aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH). Proline, glycine, cystine, basic (e.g. lysine and arginine) and acidic amino acids (e.g. glutamate and aspartate) did not inhibit [ 14 C]Lleucine uptake by S2-mock and S2-hLAT1 cells. 14 Consequently, the cell based data confirmed our previous results with rLAT1 expressing oocytes. The aim of the current work is to summarize our efforts and findings pertaining to the design and development of selective LAT1 inhibitors and to convey overall SAR findings. 
Materials and Methods
(2,3,4,5,6pentamethylphenyl)methanol, (3,5bis(trifluoromethyl)phenyl)methanol, (perfluorophenyl)methanol, (4-(trifluoromethoxy)phenyl)methanol, (2,4diethoxyphenyl)methanol, (4-methoxy-3nitrophenyl)methanol, (2,6-dimethoxypyridin-3yl)methanol were purchased from Sigma-Aldrich Chemical Company (St. Louis, MO). We monitored reactions via silica gel IB2-F thin layer chromatography (TLC) plates from J.T. Baker (Phillipsburg, NJ). Hexanes (Hex), HPLC grade methanol (MeOH), HPLC grade acetonitrile (ACN), HPLC grade water (H 2 O) and ethyl acetate (EtOAc), and Tetrahydrofuran (THF) were from Fisher Scientific (Pittsburgh, PA). We purchased silica gel, standard grade, 60A, 4-63 m from Sorbent Technologies (Norcross, GA). L-methyl-3-fluoro-tyrosine (FMT; 28) was obtained from J-Pharma LTD.
NMR and LC/MS-MS
A 400 MHz Bruker NMR, Avance III 400 was used. An Applied Biosystems Sciex 4000 (Applied Biosystems; Foster City, CA) was used and included a Shimadzu HPLC (Shimadzu Scientific Instruments, Inc.; Columbia, MD) and Leap auto-sampler (LEAP Technologies; Carrboro, NC). Using a flow-rate of 0.4 mL/min, liquid chromatography employed an Agilent Technologies, Zorbax extended-C18 50 x 4.6 mm 5 micron column. It was equipped with a column guard at 40 o C. The mobile phase consisted of A: Water, 10 mM (NH 4 OAc), 0.1% formic acid, and B: 1:1 methanol:acetonitrile. A total of 9.5 min run time, the chromatography method was 95% A held for 1.0 min; then ramped to 95% B at 3.0 min and held for 4.5 min, at which point it was brought back to 95% A at 8.5 min and held for 1.0 min. Synthesized compounds were monitored via electro-spray ionization positive ion mode (ESI+) using the following conditions: i) temperature, 450 o C; ii) curtain gas (CUR; set at 10) and Collisionally Activated Dissociation (CAD; set at 5) gas were nitrogen, iii) ion-spray voltage of 5500 V;; iv) quadruple one (Q1) and (Q3) were set on Unit resolution; v) dwell time was set at 200 msec, vi) Ion Source gas one (GS1) and two (GS2) were set at either 20 or 25,; vii) entrance potential set at 10 V; and viii) wcollision energy (CE), declustering potential (DP) and collision cell exit potential (CXP) are voltages (V). Samples ( were identified and therefore these residues were omitted from the model. The human LAT1 homology model was then subjected to energy minimization using the conjugate gradient minimization protocol (10,000 iterations) using a CHARMm forcefield and the Generalized Born implicit solvent model with simple switching. 17, 18 The flexible docking algorithm which allows for flexibility in both the ligand and receptor was used to predict the binding orientation of T3 5, T4 6, JPH203 169 and its N-acetyl metabolite 175 within the binding site of the LAT1 homology model. 19 The protein-ligand complexes then underwent energy minimization in situ using the conjugate gradient method (10,000 iterations). The following residue side chains were designated as flexible for both the docking and minimization calculations: Ser66, Ile139, Ser143, Ser144, Phe252, Ser342, and Cys407. Binding energies were calculated for each of the resulting ligand poses without solvent correction and include the loss of conformational entropy and energy of the bound ligand. 20
Synthesis: General Procedure
The corresponding di-protected (N-TFA-OMe) dihalo-tyrosine analog (2.22 mmol) was weighed into a dry round bottom flask (RBF; 100 mL) containing a stir-bar. The corresponding alcohol (2.34 mmol) and triphenylphosphine (4.46 mmol) were then added and diluted with anhydrous THF (25 mL), capped with a sure-seal and a N 2 balloon attached. The contents were stirred and cooled with an ice-bath (20 min) and then DIC (4.46 mmol) added dropwise via syringe transfer. The contents were then allowed to slowly warm to RT and stirred overnight and checked by TLC. The contents were concentrated under reduced pressure and silica gel added and subsequently purified by silica gel column chromatography; Hex  Hex:EtOAc (2:1). The isolated product was then transferred to a RBF (50 or 100 mL) containing a stir bar. THF (5 mL) was added and stirred into solution. The solution was cooled in an ice bath (20 min) and then 15 mL of ice cold 1.0 M LiOH was added. The contents were allowed to warm to ambient temperature and stirred over-night. The contents were again cooled into an ice bath (20 min) and THF removed under reduced pressure. Next, the pH was adjusted to pH ~3.0 with 3.0M HCl. The precipitant formed was collected via Büchner filtration and subsequently dried on the vacuum line overnight.
Results and Discussion
Using S2-hLAT1 and S2-hLAT2 cell lines, [ 14 C]L-leucine uptake inhibition was probed and average IC 50 values reported. 14 We compared Lphenylalanine 1 versus D-phenylalanine 13 ( Table  1; 11 M versus 96 M, respectively) which displays LAT1 was stereospecific in both species (rat and human). Compared to 1, para-hydroxy analog 14 (L-tyrosine) displayed weaker competitive inhibition (essentially two fold) in both hLAT1 and hLAT2; as a phenol (pKa ~10), 14 has an intrinsic propensity to dissociate into the anion to produce a formal charge (-1) and negatively alter substrate interactions. Replacement of phenol 14 with fluoro 15 enhanced affinity and produced a more potent inhibitor, but it was not selective with LAT1 and LAT2 IC 50 values essentially equal. Compared to 1 and 14, -methyl analogs (R 3 = methyl; 16 and 17, respectively) produce weaker substrates/inhibitors. Therefore, OH (18 and 19) , it deters substrate/inhibitor interactions and we attribute these results to steric phenomena via -OH hydrogen bonding which distort an ideal zwitterion state (-NH 3 + /-CO 2 -). While not as potent as monofluoro analog 15, difluoro 20 altered steric and electronics on the aromatic ring and produced LAT1:LAT2 selectivity; however, 20 was tested as the racemate. The change of -OH 14 to electron withdrawing nitro 21 produced a weaker LAT1 inhibitor; data further consistent with the notion that formal negative charge in this region becomes repulsive and decreases binding as previously discussed. Nitro analog 22 and iodo 23 further support the notion that electronics and steric factors in the aromatic region are critical to LAT1:LAT2 selectivity. The nitro analog has an intrinsic formal charge, while the bulky iodo does not. Interesting enough, the modification of monoiodo 23 to di-iodo analog 24 began to produce compounds with moderate LAT1:LAT2 selectivity. Hindered 25 display the location where steric hindrance and subtle differences, relative to the amino acid, exist between LAT1 and LAT2. The amine location (1 versus 26) further supports the notion that tight charge distance between amine and carboxylic are required. Carboxylic acid 14 compared to alcohol 27 also support the amino acid zwitterion requirement. Comparing -methyl 15 to -methyl-fluoro 28 (FMT), both compounds display LAT1:LAT2 selectivity with the additional EWG decreasing LAT1 IC 50 from 75 M to 54 M, respectively. Lastly, to further demonstrate the structural importance of the amino acid zwitterion state (-NH 3 + /-CO 2 -), we also tested compounds with modified -NH 2 such as indole 29, isoquinoline 30, L-pyroglutamic acid 31, 4hydroxy-L-proline 32, and also replacement of -NH 2 with -OH, (R)-mandelic acid 33 and (S)mandelic acid 34; all of these compounds did not readily display LAT1 or LAT2 14 C-Leu uptake inhibition.
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Figure 1
The experimental data summarized in Table 1 demonstrate intrinsic chemical requirements to inhibit LAT1 amino acid substrates (i.e. 14 C-Leu). However, these data do not fully convey their potential as substrates. FMT is clinically important; the radiolabeled analog 18 21 Using hLAT1 and hLAT2 expressing oocytes and LC/MS-MS analysis, we sought to investigate uptake of 16 (MW = 195) and FMT 28 (MW = 215). Presented in Figure 2 , are oocyte uptake experiments -methyl-tyrosine 16 transport via LAT1 was faster than -methyl-fluoro-tyrosine 28; 16 and 28 displayed linear uptake at 5.0 M (1.0 hr), while transport into the oocyte was saturable at 50.0 M (K m 27.1 ± 0.8 M and 40.3 ± 0.8 M, respectively). Compared to the LAT2 transport resultssee supplementary materials sectionboth 16 and 28 displayed good LAT1 transport and inhibitory selectivity ( Table 1) . These features illustrate that a good PET probe such as 18F-FMT with an IC 50 of LAT1 54 M has room for improvement in the diagnostic area.
Figure 2
Since 2002, chemistry efforts in our laboratories have produced potent and LAT1 selective compounds. [22] [23] The stereospecific zwitterion amino acid containing an aromatic ring (e.g. phenylalanine, tyrosine) comprises the LAT1 binding site (A-C; Figure 3 ). All experimental data suggest: i) amino acid functionality is required for binding (A) 13 ; ii) amino acid L-stereochemistry is preferred and LAT1 may tolerate a methyl group at the alpha carbon (B); and iii) aromatic amino acids are preferred and size/electronic effects (C) clearly influence the substrate-inhibitor binding pocket interface. Iodo 23 and di-iodo 24 ( Table 1) provided initial insight into how subtle differences in size and electronics ~5 o A away from the alpha carbon (Figure 3 ) may affect substrate/inhibitor properties. In addition to compounds in Table 1 , we also tested DL-3-(2-naphthyl)-alanine 37, Lhomophenyl alanine 38, and 3-(thianaphthen-3-yl)-L-alanine 39 (Figure 1) which afforded 14 C-Leu uptake S2-LAT1:S2-LAT2 IC 50 's (M) of 30:112, 11:61 and 2.5:9.5, respectively. These data further confirmed that relative distance from the amino acid functionality and steric/electronic interactions are critical factors dictating LAT1:LAT2 selectivity. As we sought to fully understand the structural requirements to produce potent and selective LAT1 compounds, we systematically prepared and tested compounds containing the tyrosine chemical template.
Figure 3
The general synthetic scheme to prepare compounds is presented in Figure 4 . We prepared mono-and di-halogenated L-tyrosine compounds: monochloro 40, dichloro 41, dichloro--methyl 42, and dibromo 43. The amino acid functionality for these compounds and di-iodo 24 were di-protected by converting to their methyl esters followed by amine protection (-COCF 3 ) to give analogs 44 -48, respectively. Mono-iodo 23 and di-iodo 24 were previously discussed ( Table 1) ; consistent with the iodo series, di-chloro 41 (37:NI M; NI = no inhibition at 150 microM) was not as potent as mono-chloro 40 (19:12 M) but displayed more profound LAT1:LAT2 selectivity. Hence, it is within this region where the first differences between LAT1 and LAT2 are experimentally observed; where amino acid analog molecular size begins to significantly influence selectivity and transport rates. We have termed this region as the "substrate-inhibitor interface" (Figure 3, C and D) . Next, the di-protected di-halo-tyrosine compounds were chemically coupled with various alcohols and deprotected to produce a series of di-chloro (49 -96; Table 2 ), di-bromo (97 -132; Table 3 ) and diiodo (133 -168; Table 4 ) tyrosine compounds. These compounds were screened in the S2-hLAT1 and S2-hLAT2 cell system to afford the 14 C-Leu uptake inhibition data.
Figure 4
Copyright 2019 KEI Journals. All Rights Reserved http://journals.ke-i.org/index.php/mra The data summarized in Tables 2-4 produced general trends: i) overall, di-chloroanalogs exert a better fit within the LAT1 binding/substrate pocket than their corresponding di-bromo and di-iodo analogs (e.g. compare 49, 97 to 137; and also compare 64, 111 to 154); and ii) that electronic and/or hydrogen bonding interactions far from the amino acid may significantly influence inhibitor potency. To help illustrate this major finding, we have summarized a series of potent LAT1 inhibitors (Figure 4 & Table 5 ) which maintain the dichloro-tyrosine functionality but modified with aro-substituted benzo[d]oxazol-5-amines (169 -176). Compound 169 (JPH203) has a low nano-molar in vitro inhibitory activity and the importance of the aryl amine may be exemplified by comparing 169 to dimethyl analogs 170 -174 resulting in altered IC 50 LAT1 values. 24 Region E (Figure 3) contains limited space but may accommodate minor modifications such as -NHCOMe, -NHMe, -NMe 2 , -F, -CF 3 ; the metabolite of JPH203 169, NAc-JPH203 175 , was an active metabolite albeit a weaker LAT1 inhibitor. 25 Comparing 170 to benzofuran 171 demonstrates the importance of the nitrogen atom in region F (Figure 3) . Modifying phenylbenzo[d]oxazol-5-amine 170 with a nitrogen atom in the para-, meta-or ortho-position (172, 173 and 174, respectively; Table 5 ) produced weaker LAT1 inhibitors. Amine 176, compared to 173 ( Table 5 ), further illustrates that -NH 2 is preferred (region E, Figure 3 ) and that slight secondary pocket modification may have profound changes in inhibitory potency. The phenyl ring, region G, should not be electronically distorted with a hydrogen-bonding group (e.g. pyridinyl or phenol) as they significantly alter both inhibitor potency and/or LAT1:LAT2 selectivity. We know from examples 169 versus 177 ( Table 5 ) that hydrogen bonding and the ability to form a formal charge in the inhibitory pocket severely alters LAT1:LAT2 selectivity (consistent with observations previously discussed, Tables 1 -4). Overall, JPH203 was well tolerated and had promising results in biliary tract cancer. Regarding computational analysis, the binding orientation of Arg transferred into the homology model from the crystal structure template indicates that the predicted binding site for the amino acid moiety is comprised of Ser66, Gly67, Phe252, Ala253, and Gly255, while the basic side chain occupies a binding pocket consisting of Ile139, Ile140, Ser342, Thr345, and Cys407 (JPH203, Figure 5 ). In silico small molecule docking of T3, T4, JPH203 and NAc-JPH203 indicates the amino acid moiety of the compound to bind in a manner similar to Arg, (Supplementary Figure 3) with the amine substituent occupying the binding site of the basic side chain and the phenyl ring occupying an adjacent hydrophobic pocket consisting of Phe95, Met415, Phe445, and Val449. Although the amino acid moiety of the NAc JPH203 ( Supplementary  Figure 4 ) metabolite is predicted to bind the amino acid binding site, the region where the primary amine of the parent compound is predicted to bind does not appear to have the capacity to accommodate the N-acetyl group. Therefore the binding orientation of the NAc derivative is predicted to be flipped across the ester bond compared to the parent compound, with the NAc group predicted to occupy the hydrophobic pocket (Supplementary Figure 4) . This resulted in a substantially less favorable predicted binding energy for metabolite NAc-JPH203 (-73.9 kcal/mol vs -163.7 kcal/mol). This is consistent with our in vitro LAT1 activity data indicating a rough 5-fold higher IC 50 for the metabolite compared to JPH203. 25 The in vitro LAT1 inhibitory trend for these compounds was 169 > 175 > 5 > 6 and consistent with an in silico binding energy trend (kcal/mol) of -198.8 > -138.5 > -132.4 > -65.2, respectively.
To our knowledge, this is the first report providing a summary regarding LAT1 substrate/inhibitor interface and how subtle differences in the various regions within LAT1 versus LAT2 exist. Herein, we provide historical aspects regarding initial Structure Activity Relationship (SAR) findings reported in 2002 with the oocyte model and in 2008 with S2-LAT1 and S2-LAT2 cell lines. We summarize a series of dichloro-dibromo-and diiodo-tyrosine analogs, and tested their potential to inhibit leucine transport in vitro to afford IC 50 values with a few being low microM LAT1 inhibitors. We then summarize our efforts regarding novel LAT1 inhibitors with sub-nanomolar (nM) IC 50 's to produce JPH203. We describe differences observed between LAT1 and LAT2. Overall, we provide an expanded SAR model regarding potent and selective LAT1 inhibitors.
